Sorrento Therapeutics (SRNE) TRIBECA Enrollment on Track; Aegis Affirms at 'Buy'
Tweet Send to a Friend
Aegis Capital affirms Sorrento Therapeutics, Inc. (Nasdaq: SRNE) at Buy with a price target of $35 following an update on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
